Effect of body mass index on the outcome of children with acute myeloid leukemia

The effect of body mass index (BMI) on the treatment outcomes of children with acute myeloid leukemia (AML) is unclear and needs further evaluation.

[1]  J. Buckley,et al.  Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: a report from the Children's cancer group study CCG-2891. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  David W. Henry,et al.  Obesity in pediatric oncology , 2005, Pediatric blood & cancer.

[3]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[4]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[5]  S. Raimondi,et al.  Treatment of childhood acute myelogenous leukemia with an intensive regimen (AML-87) that individualizes etoposide and cytarabine dosages: short- and long-term effects , 2000, Leukemia.

[6]  R. Gray,et al.  Spline-based tests in survival analysis. , 1994, Biometrics.

[7]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[8]  E. Estey,et al.  Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia , 2012, Haematologica.

[9]  S. Raimondi,et al.  Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Hyland,et al.  Is obesity a prognostic factor for acute myeloid leukemia outcome? , 2012, Annals of Hematology.

[11]  D.,et al.  Regression Models and Life-Tables , 2022 .

[12]  P. Wiernik,et al.  FACTORS EFFECTING REMISSION AND SURVIVAL IN ADULT ACUTE NONLYMPHOCYTIC LEUKEMIA (ANLL) , 1970, Medicine.

[13]  A. Bleyer,et al.  Obesity and outcome in pediatric acute lymphoblastic leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  E. Frongillo,et al.  Estimates of global prevalence of childhood underweight in 1990 and 2015. , 2004, JAMA.

[15]  D. Olive,et al.  in patients with acute myeloid leukemia triggering receptors - Defective expression and function of natural killer cell , 2013 .

[16]  Dario Campana,et al.  Combination of Cladribine and Cytarabine is Effective for Childhood Acute Myeloid Leukemia: Results of the St. Jude AML97 Trial , 2009, Leukemia.

[17]  R. Hills,et al.  Independent Prognostic Factors for Aml Outcome Pre-treatment Prognostic Factors , 2022 .

[18]  Elaine Coustan-Smith,et al.  Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. , 2010, The Lancet. Oncology.

[19]  R. Hanada,et al.  Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Herbert Tilg,et al.  Adipocytokines: mediators linking adipose tissue, inflammation and immunity , 2006, Nature Reviews Immunology.

[21]  D. Rushing,et al.  Doxorubicin clearance in the obese. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  RK Chandra,et al.  Nutrition and the immune system from birth to old age , 2002, European Journal of Clinical Nutrition.

[23]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[24]  P. Thall,et al.  Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia , 1997, Leukemia.

[25]  Ching-Hon Pui,et al.  Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. , 2006, Blood.

[26]  K. Flegal,et al.  Prevalence of high body mass index in US children and adolescents, 2007-2008. , 2010, JAMA.

[27]  Todd A Alonzo,et al.  Mortality in overweight and underweight children with acute myeloid leukemia. , 2005, JAMA.

[28]  R. Foà,et al.  Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols. , 2012, Blood.

[29]  W. Kruskal,et al.  Use of Ranks in One-Criterion Variance Analysis , 1952 .